Accreditation

0.5 AMA PRA Category 1 Credit(s)™.
Read the full Accreditation Statement

Target Audience

This activity will be directed to rheumatologists, gastroenterologists, dermatologists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals interested in or using biologic therapeutics in autoimmune and inflammatory disorders.

Description

This activity was presented at the Cleveland Clinic Richard J. Fasenmyer Center of Clinical Immunology Biologic Therapies for Autoimmune and Inflammatory Disease States Summit. The summit reviewed advances in biologic therapies for autoimmune diseases.

Objectives

At the conclusion of this activity, the participant will be able to:

1. Recognize first-line therapy for the patient with active rheumatoid arthritis that is inadequately responsive to methotrexate therapy.
2. Describe therapeutic options available to the patient with active rheumatoid arthritis that remains inadequately responsive to an anti-TNF agent.
3. Discuss safety issues regarding the use of biologic agents to treat rheumatoid arthritis.

Activity Director

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology

Author

Jonathan Kay, MD

Faculty Disclosure

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest: